Figure 3

Analysis of TC-1 tumor infiltrating lymphocytes after treatment. Groups of female C57BL/6 mice (5 per group) were injected with 3 × 10⁴ of TC-1 tumor cells subcutaneously. Five days after tumor cell injection, the mice were treated through intraperitoneal injection with one of the following regimens: vehicle, bortezomib alone (1 mg/kg, once every 3 days), SAHA alone (30 mg/kg, once per day), or the combination of bortezomib and SAHA as described in Figure 1A. 4 days after last treatment, the tumors were resected from the mice and the single tumor cell suspension cells were prepared by enzymatic digestion. The cells were then stained with anti-mouse CD3, CD4 and CD8, or stimulated with HPV16 E7aa49-57 peptide at the presence of GolgiPlug overnight followed by flow cytometry analysis A. Representative of CD3 and CD8 staining images of TC-1 tumor single cell suspension. B. Summary of the infiltrating CD3⁺CD8⁺ T cells in TC-1 tumor. C. Summary of CD3⁺CD4⁺/CD3⁺CD8⁺ ratio of infiltrating lymphocytes in TC-1 tumor. D. Representative of IFN-γ intracellular staining images of TC-1 tumor infiltrating CD8+ T cells. E. Summary of IFN-γ intracellular staining data of TC-1 tumor infiltrating CD8+ T cells.